| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 1,900 | ₹1.05 -66.66% | 450-33.33% |
| - | - | 2,000 | ₹3.2 -54.28% | 2,250900% |
| - | - | 2,050 | ₹4.75 -43.78% | 6,750500% |
| 2250% | ₹267.5 0% | 2,100 | ₹9.5 -43.28% | 39,1502.95% |
| - | - | 2,150 | ₹14.4 -39.62% | 12,82521.27% |
| 2250% | ₹185 0% | 2,200 | ₹25.1 -33.42% | 41,40052.06% |
| 1,800700% | ₹136.35 9.07% | 2,250 | ₹37.5 -30.1% | 7,87566.66% |
| 76,050-8.40% | ₹104 10.46% | 2,300 | ₹54 -26.82% | 49,72514.50% |
| 15,300119.35% | ₹77 10.07% | 2,350 | ₹75.15 -20.89% | 4,7252000% |
| 95,175-15.23% | ₹56.7 11.28% | 2,400 | ₹107.8 -17.42% | 22,275-1% |
| 13,725144% | ₹40 3.49% | 2,450 | - | - |
| 51,52529.37% | ₹26.5 8.38% | 2,500 | ₹162.65 -19.11% | 11,9256% |
| 10,12515.38% | ₹18 -6.73% | 2,550 | - | - |
| 32,400118.18% | ₹11.15 4.69% | 2,600 | ₹247.5 -13.62% | 2,25011.11% |
| 1,125150% | ₹7.15 -4.02% | 2,650 | - | - |
| 17,775139.39% | ₹4.75 2.15% | 2,700 | - | - |
| 3,600166.66% | ₹2.05 -30.5% | 2,800 | - | - |
The business said that it logged a 10.70% year-on-year decline in its consolidated net profit at ₹420.80 Crore for Q4FY25.
Here are some of the stocks that may see significant price movement today: NBCC, IndusInd Bank, Hindustan Zinc, etc.
The cumulative demand, including interest charges, is ₹183.11 crore.
The merger took effect on March 29, 2025, after all necessary regulatory approvals were obtained.
The tax adjustments pertain to Section 80IC/80IE, which involves deductions for businesses in special economic zones, and a disallowance of certain expenditures under Section 37(1) of the Act.
Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.
The company reported a good growth in EBITDA of 36.8% to ₹830 crore in the quarter against ₹606.5 crore in Q3 FY24.
The NCDs issued are categorized, rated, secured, redeemable, and transferable, distributed across three series.
According to the National Cancer Registry Programme, cancer is expected to cause 29.8 million DALYs by 2025, making it a serious health issue in India.
The issue price includes a premium of ₹2,519 per share, aggregating a total of ₹2,999.99 crore.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
